My Name is Alick Torchinsky and for over twenty-five years I was the Chief, dept. of Pharmacy at the Jewish General Hospital, a major university teaching hospital in Montreal. During this time I was a Co-chair of the infection-control committee- and Chairman of the oncology pharmacy group of the McGill oncology research division. I became concerned by the lack of a successful treatment for fungal growth in the mouth and throat, which plagues AIDS, cancer and other immuno-compromised patients.
I have developed an antiseptic oral rinse which has been clinically tested by doctors from the McGill University faculties of Dentistry and Medicine. The therapy is completely effective and less expensive with a 3 years shelf life making it ideal for patients with AIDS in Africa. A full report is available for your review. Please write to me at firstname.lastname@example.org
I have teamed up with Jack Miller and Dr. Emmanuel Crezoit, to make this treatment available to the people who need it. Jack has 30 years of experience developing medications for cholesterol, ophthalmology and diabetes. Dr Crezoit is the Chef du Service du Centre Hospitalier Universitaire (C.H.U.)
We need your help to raise the funds for the regulatory approval to be able to distribute the therapy to patients in Africa.
All THE DETAILS - Please take the time to get informed
Oral fungal infections are common in AIDS and Cancer patients. The symptoms include painful ulcerations, redness and swelling in the mouth which is often hidden by an overgrowth of Candida. Severe symptoms may prevent patients from eating to the extent that hospitalization and intravenous nutrition is required. The infections can interrupt their treatment.
In Canada and the USA, an estimated 400,000 patients suffer from oral mucositis associated with cancer treatment (75%-100% of patients receiving higher doses of chemotherapy). Oral mucositis and Candida overgrowth affects nearly 100% of patients with head and neck cancer receiving radiation therapy as well as patients receiving radiation therapy in the upper half of the chest.
The extent of complications of oral mucositis is much greater in Africa and other developing countries where HIV-AIDS is epidemic. There are over 30,000,0000 infected patients in Africa alone. The poorer sanitary conditions results in a greater incidence of the disease.
Many products are available which have relatively poor results. These products consist of many anti fungal products and oral solutions. These antifungal agents are very expensive to both the patients and hospital budgets. Acquisition, preparation and administration costs are high. The results are limited and must be repeated often. In most cases these antifungal, both topical and systemic have very poor activity against Krucera, a major Candida strain. Our new patented mouth wash has been shown to be the most effective. Laboratory studies have shown that the solution not only stops but lyses (kills) this strain. The competitive oral liquids and special antiseptics/antibacterial have an even lesser effect and do not kill Candida - Krucera.
Study 1 Boivin G. HSV -1 versus le produit antiseptique. Centre de recherche en infectoliologie, Sainte-Foy, Quebec. 2-11-01.
Study 2 Eyamie JR, Chan ECS. In Vitro Effectiveness of Chlorhexidine-containing Mouthrinses Against Candida Isolates. Department of Microbiology and Immunology, McGill University, Montreal, Quebec. April, 1996.
Study 3 Susceptibility of Yeasts and Bacteria of Oral Origin to a New Mouthrinse Containing Chlorhexidine. 91-09-13.
Study 4 Chan ECS. Summary of the Results Obtained on Testing the Mouth-wash Solutions Against Oral Microorganisms. Department of Oral Biology, McGill University, Montreal, Quebec. April 2, 1990.
Study 5 Chan ECS. Report on a Laboratory Study of Virkon to Be Used as a Mouthwash. Faculty of Dentistry, McGill University, Montreal, Quebec.
Study 6 Gornitsky M. Report on the Utilization of the Original Formula of Mouthwash in Treatment of Candidiasis in Patients
Our product is not expensive enough to interest the large pharmaceutical companies and we want to make sure that it is affordable to patients who do not have the means for expensive drugs. It is too expensive to get regulatory approval in North America. We have developed the necessary relationships with the Ivory Coast Minister of Health, the Minister of AIDS, the senior hospital administrator and Dr. Crezoit a senior physician who will act as the lead clinical investigator, for approval to conduct a clinical trial to replicate the already demonstrated clinical efficacy. We have already produced enough clinical trial material to treat 120 people and it is already in the hospital awaiting the start of the study. The clinical trial is scheduled to run for 3 to 6 months subject to patient enrolment. Upon its conclusion and demonstration of efficacy, the UN and American AIDS program will be the primary recipients for the product for distribution to their AIDS programs within Africa.